US FDA classifies respiratory viral panel multiplex nucleic acid assays
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a final rule classifying respiratory viral panel multiplex nucleic acid assay devices as Class II (medium-risk)1,2.